Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mouth Rinses Efficacy on Salivary SARS-CoV-2 Viral Load
NCT04721457Phase 4Completed
- Sponsor
- King Abdulaziz University
- Start
- Jan 2021
- Primary completion
- Mar 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of povidone-iodine, hydrogen peroxide, cetylpyridinium chloride and sodium hypochlorite in coronavirus disease 2019 (COVID-19) (6 arms), sponsored by King Abdulaziz University. Primary endpoints: Change in the salivary viral load within each mouth rinse groups and controls and Compare salivary viral load between mouth rinse groups and controls. Started Jan 2021; status: completed.
02
Drugs
povidone-iodinehydrogen peroxidecetylpyridinium chloridesodium hypochlorite
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04721457.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04721457.